Q4FY24 Quarterly & FY24 Annual Result Announced for Ipca Laboratories Ltd.
Pharmaceuticals company Ipca Laboratories announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Standalone Net total Income up 6% at Rs 1,525.72 crore. Consolidated Net total Income up 33% at Rs 2,051.93 crore. Indian formulations income up 13% at Rs 689.83 crore. Exports Income up 7% at Rs 731.38 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.50% in Q4 FY24 as against @ 11.75% in Q4 FY23. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items).@ 14.98% in Q4 FY24 as against @11.29% in Q4 FY23. Standalone Net Profit at Rs 64.76 crore (after exceptional items) down 24%. Consolidated Net Profit at Rs 59.59 crore (after exceptional items) down 22%. The Board has recommended final dividend of Rs 2/- per share (200%) FY24 Financial Highlights: Standalone Net Total Income up 6% at Rs 6,111 crore. Consolidated Net Total Income up 23% at Rs 7,829.81 crore. Indian formulations income up 12% at Rs 3,097.16 crore. Exports Income up 2% at Rs 2,707.70 crore. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 19.29% in FY24 as against @ 16.22% in FY23 Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 16.72% in FY24 as against @ 15.35% in FY23 Standalone Net Profit at Rs 530.41 crore (after exceptional items) up 5%. Consolidated Net Profit at Rs 547.35 crore (after exceptional items) up 16% Result PDF29-05-2024